Predictors of mucosal melanoma survival in a population-based setting - 21/06/19
, Megan Eguchi, MPH b, David H. Peng, MD, MPH a, Myles Cockburn, PhD a, b, cAbstract |
Background |
Mucosal melanomas are rare and aggressive neoplasms, with little published population-based data on predictors of survival.
Objective |
We sought to assess the influences of race/ethnicity, sex, tumor stage, tumor thickness, and anatomic site on mucosal melanoma survival estimates.
Methods |
We analyzed 132,751 cases of melanoma, including 1824 mucosal melanomas, diagnosed between 1994 and 2015 and reported to the California Cancer Registry. Kaplan–Meier survival analysis and Cox proportional hazards regression assessed the prognostic variables.
Results |
The 5-year relative survival for mucosal melanomas (27.64% [95% confidence interval {CI} 25.42-29.91) was significantly lower than for cutaneous melanomas (76.28% [95% CI 76.03-76.53]). Stage independently influenced survival, and thickness did not predict survival for neoplasms of known depth. Less common anatomic sites conferred worse prognoses (hazard ratio 1.93 [95% CI 1.41-2.64]).
Limitations |
The lack of a standardized staging system may have resulted in misclassification of stage for some neoplasms. The influence of genetics is unknown because our database did not contain genetic characteristics.
Conclusions |
Stage and anatomic site, but not thickness (ie, Breslow depth), race, or ethnicity, determine the prognosis of mucosal melanomas. Considering the poor prognosis for all stages of mucosal melanoma, dermatologists should incorporate examination of the oropharynx and genitalia in the full body skin examination.
Le texte complet de cet article est disponible en PDF.Key words : California Cancer Registry, epidemiology, extracutaneous melanoma, mucosal melanoma, population-based, survival, treatment
Plan
| Dr Cockburn was supported in part by the National Cancer Institute's Surveillance, Epidemiology and End Results Program under contract HHSN261201000140C awarded to the Cancer Prevention Institute of California, contract HHSN261201000035C awarded to the University of Southern California, and contract HHSN261201000034C awarded to the Public Health Institute, and the Centers for Disease Control and Prevention's National Program of Cancer Registries, under agreement U58DP003862-01 awarded to the California Department of Public Health. |
|
| Coflicts of interest: None disclosed. |
Vol 81 - N° 1
P. 136 - juillet 2019 Retour au numéro
Article précédent
- Characterization of chronic urticaria and associated conditions in a large population of adolescents
- Yossi Rosman, Alon Y. Hershko, Keren Meir-Shafrir, Ron Kedem, Idit Lachover-Roth, Yoseph A. Mekori, Ronit Confino-Cohen
- Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort
- Sarah Faiz, Jonathan Giovannelli, Céline Podevin, Marie Jachiet, Jean-David Bouaziz, Ziad Reguiai, Audrey Nosbaum, Audrey Lasek, Marie-Christine Ferrier le Bouedec, Aurélie Du Thanh, Nadia Raison-Peyron, Florence Tetart, Anne-Bénédicte Duval-Modeste, Laurent Misery, François Aubin, Anne Dompmartin, Cécile Morice, Catherine Droitcourt, Angèle Soria, Jean-Philippe Arnault, Juliette Delaunay, Emmanuel Mahé, Marie-Aleth Richard, Amélie Schoeffler, Jean-Philippe Lacour, Edouard Begon, Amélie Walter-Lepage, Anne-Sophie Dillies, Sandrine Rappelle-Duruy, Stéphane Barete, Nathalia Bellon, Nathalie Bénéton, Aude Valois, Sébastien Barbarot, Julien Sénéchal, Delphine Staumont-Sallé, Groupe de Recherche sur l'Eczéma aTopique (GREAT), France
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?